Amicus Therapeutics Inc [FOLD] stock is trading at $8.48, up 6.40%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The FOLD shares have gain 5.74% over the last week, with a monthly amount glided 15.53%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amicus Therapeutics Inc [NASDAQ: FOLD] stock has seen the most recent analyst activity on September 18, 2025, when Needham upgraded its rating to a Buy but kept the price target unchanged to $14 for it. Previously, Morgan Stanley upgraded its rating to Overweight on July 17, 2025, and kept the price target unchanged to $108. On December 13, 2024, downgrade downgraded it’s rating to Equal-Weight and revised its price target to $12 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $18 on September 06, 2024. Wells Fargo initiated its recommendation with a Overweight and recommended $18 as its price target on May 30, 2024. Guggenheim upgraded its rating to Buy for this stock on May 14, 2024, but kept the price target unchanged to $13. In a note dated December 19, 2023, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $15 to $20.
Amicus Therapeutics Inc [FOLD] stock has fluctuated between $5.51 and $12.65 over the past year. Currently, Wall Street analysts expect the stock to reach $14 within the next 12 months. Amicus Therapeutics Inc [NASDAQ: FOLD] shares were valued at $8.48 at the most recent close of the market. An investor can expect a potential return of 65.09% based on the average FOLD price forecast.
Analyzing the FOLD fundamentals
Amicus Therapeutics Inc [NASDAQ:FOLD] reported sales of 571.16M for the trailing twelve months, which represents a growth of 22.12%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at 0.04%, Pretax Profit Margin comes in at -0.04%, and Net Profit Margin reading is -0.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.2 and Total Capital is 0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Amicus Therapeutics Inc’s Current Ratio is 3.21. Further, the Quick Ratio stands at 2.29, while the Cash Ratio is 0.95. Considering the valuation of this stock, the price to sales ratio is 4.58, the price to book ratio is 12.79.
Transactions by insiders
Recent insider trading involved Campbell Bradley L, President and CEO, that happened on Feb 19 ’25 when 400.0 shares were sold. Director, BRADLEY CAMPBELL completed a deal on Feb 19 ’25 to buy 400.0 shares. Meanwhile, President and CEO Campbell Bradley L sold 7500.0 shares on Dec 02 ’24.
